JP2000271189A - Suppository packing body and manufacture therefor - Google Patents
Suppository packing body and manufacture thereforInfo
- Publication number
- JP2000271189A JP2000271189A JP11078691A JP7869199A JP2000271189A JP 2000271189 A JP2000271189 A JP 2000271189A JP 11078691 A JP11078691 A JP 11078691A JP 7869199 A JP7869199 A JP 7869199A JP 2000271189 A JP2000271189 A JP 2000271189A
- Authority
- JP
- Japan
- Prior art keywords
- suppository
- container
- filler
- space
- package
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000829 suppository Substances 0.000 title claims abstract description 221
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 17
- 238000012856 packing Methods 0.000 title abstract 3
- 239000000945 filler Substances 0.000 claims abstract description 50
- 238000007789 sealing Methods 0.000 claims abstract description 21
- 239000004831 Hot glue Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 10
- 230000036760 body temperature Effects 0.000 abstract description 8
- 239000011800 void material Substances 0.000 abstract description 7
- 238000002844 melting Methods 0.000 abstract description 5
- 230000008018 melting Effects 0.000 abstract description 5
- -1 polyethylene Polymers 0.000 description 23
- 230000001070 adhesive effect Effects 0.000 description 13
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 239000000853 adhesive Substances 0.000 description 11
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000009826 distribution Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 239000002861 polymer material Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 229920005615 natural polymer Polymers 0.000 description 3
- 229920001059 synthetic polymer Polymers 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 229920002367 Polyisobutene Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000005037 alkyl phenyl group Chemical group 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229920003002 synthetic resin Polymers 0.000 description 2
- 239000000057 synthetic resin Substances 0.000 description 2
- SZHOJFHSIKHZHA-UHFFFAOYSA-N tridecanoic acid Chemical compound CCCCCCCCCCCCC(O)=O SZHOJFHSIKHZHA-UHFFFAOYSA-N 0.000 description 2
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 235000019871 vegetable fat Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- JHWNWJKBPDFINM-UHFFFAOYSA-N Laurolactam Chemical compound O=C1CCCCCCCCCCCN1 JHWNWJKBPDFINM-UHFFFAOYSA-N 0.000 description 1
- 241000604893 Lindera umbellata Species 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 229920000571 Nylon 11 Polymers 0.000 description 1
- 229920000299 Nylon 12 Polymers 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 241001237745 Salamis Species 0.000 description 1
- 241001419723 Scopolia carniolica Species 0.000 description 1
- XRHTZVUDPQWCBD-MLWYYCKJSA-N Stearyl linoleate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCC\C=C/C\C=C/CCCCC XRHTZVUDPQWCBD-MLWYYCKJSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000006732 Torreya nucifera Nutrition 0.000 description 1
- 244000111306 Torreya nucifera Species 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 229960000503 bisacodyl Drugs 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 229960001889 buprenorphine hydrochloride Drugs 0.000 description 1
- UAIXRPCCYXNJMQ-RZIPZOSSSA-N buprenorphine hydrochlorie Chemical compound [Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)C[NH+]2CC1CC1 UAIXRPCCYXNJMQ-RZIPZOSSSA-N 0.000 description 1
- DHAZIUXMHRHVMP-UHFFFAOYSA-N butyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCC DHAZIUXMHRHVMP-UHFFFAOYSA-N 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229960000636 ceftizoxime sodium Drugs 0.000 description 1
- ADLFUPFRVXCDMO-LIGXYSTNSA-M ceftizoxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=CCS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 ADLFUPFRVXCDMO-LIGXYSTNSA-M 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- KYBOHGVERHWSSV-VNIVIJDLSA-N gemeprost Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(=O)OC KYBOHGVERHWSSV-VNIVIJDLSA-N 0.000 description 1
- 229960003480 gemeprost Drugs 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229960005195 morphine hydrochloride Drugs 0.000 description 1
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002037 poly(vinyl butyral) polymer Polymers 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920005672 polyolefin resin Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- XEIOPEQGDSYOIH-MURFETPASA-N propan-2-yl (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC(C)C XEIOPEQGDSYOIH-MURFETPASA-N 0.000 description 1
- 235000015175 salami Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000003566 sealing material Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229920002725 thermoplastic elastomer Polymers 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/08—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of suppositories or sticks
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は坐剤をコンテナ内に
包含した状態で保存又は流通過程におかれる坐剤梱包体
及びその製造方法に関し、特に、高温下での保存及び流
通に好適な坐剤梱包体及びその製造方法に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a suppository package in which a suppository is stored or distributed in a state in which the suppository is contained in a container, and a method for producing the same, and more particularly to a suppository suitable for storage and distribution at high temperatures. The present invention relates to an agent package and a method for manufacturing the same.
【0002】[0002]
【従来の技術】一般に、坐剤は油脂性基剤に薬物等を添
加混合して製造されており、プラスチック製の坐剤用コ
ンテナによって梱包された状態で保存又は流通過程にお
かれている。坐剤の融点は通常30〜37℃程度に設定
されており、坐剤は室温では固体状態を保つが直腸内に
おいて体温により融解して薬物を放出するので、直腸粘
膜から吸収させることが好ましい薬物の投与に広く使用
されている。2. Description of the Related Art In general, suppositories are prepared by adding a drug or the like to an oily base, and are stored or distributed in a state of being packed in a plastic suppository container. The suppository usually has a melting point of about 30 to 37 ° C., and the suppository maintains a solid state at room temperature, but melts in the rectum due to body temperature to release the drug. Widely used for the administration of
【0003】[0003]
【発明が解決しようとする課題】ところで、坐剤の保存
及び流通過程においては保冷、並びに、横転乃至天地逆
転の禁止が必須である。これは、体温以上の温度環境下
で坐剤を保存又は流通させると坐剤用コンテナ内で坐剤
が溶融して変形する恐れがあるからである。特に、坐剤
用コンテナが横転又は天地逆転した状態で坐剤が溶融す
ると、該コンテナ内で坐剤が移動して坐剤形状が大きく
変形する。そして、この状態で温度が低下すると、変形
したまま坐剤が固化してしまうので商品価値が低下する
のみならず、直腸内への挿入が困難になり使用不可とな
る場合もある。By the way, in the process of storing and distributing suppositories, it is essential to keep cool and to prohibit rollover or upside down. This is because if the suppository is stored or distributed under a temperature environment equal to or higher than the body temperature, the suppository may be melted and deformed in the suppository container. In particular, when the suppository is melted in a state where the suppository container is turned upside down or upside down, the suppository moves in the container and the suppository shape is largely deformed. If the temperature drops in this state, the suppository solidifies while being deformed, which not only reduces the commercial value, but also makes it difficult to insert it into the rectum, making it unusable.
【0004】しかしながら、これまでのところ、いかに
保冷並びに横転乃至天地逆転禁止を心がけたとしても、
取扱者の過失乃至不可抗力等によって、坐剤の変形を完
全に防止することは不可能であった。[0004] However, no matter how far the cooling and the prohibition of rollover or upside-down rotation have been attempted,
It was impossible to completely prevent deformation of the suppository due to negligence or force majeure of the handler.
【0005】本発明は坐剤の保存乃至流通段階における
上記した問題点を解決することをその課題とする。すな
わち、本発明の目的は、体温以上の温度環境下において
保存又は流通過程に置かれたとしても、坐剤が熱によっ
て変形することのない新規な坐剤梱包体及びその製造方
法を提供することにある。An object of the present invention is to solve the above-mentioned problems at the stage of storing or distributing suppositories. That is, an object of the present invention is to provide a novel suppository package in which a suppository is not deformed by heat, even when stored or distributed in a temperature environment equal to or higher than body temperature, and to provide a method for producing the same. It is in.
【0006】[0006]
【課題を解決するための手段】本発明の坐剤梱包体は、
坐剤と、前記坐剤を包含するコンテナとからなる坐剤梱
包体であって、前記坐剤と前記コンテナとの間の空間に
充填材が封入されていることを特徴とする。前記充填材
は前記コンテナと接合されていることが好ましく、特
に、前記コンテナがシール部を備えており、前記充填材
が該シール部と一体化されていることがより好ましい。SUMMARY OF THE INVENTION The suppository package of the present invention comprises:
A suppository package comprising a suppository and a container containing the suppository, wherein a filler is sealed in a space between the suppository and the container. The filler is preferably joined to the container, and more preferably, the container is provided with a seal, and more preferably, the filler is integrated with the seal.
【0007】また、本発明の坐剤梱包体においては、前
記充填材が溶出成分を含まないことが好ましく、とりわ
け、前記充填材がホットメルト型接着剤であることが好
ましい。なお、前記「溶出成分」とは、何らかの作用乃
至条件下において充填材から該充填材の外部へ溶出する
あらゆる物質を指す。In the suppository package of the present invention, it is preferable that the filler does not contain an eluted component, and it is particularly preferable that the filler is a hot-melt adhesive. The “eluting component” refers to any substance that elutes from the filler to the outside of the filler under any action or condition.
【0008】そして、本発明の坐剤梱包体の製造方法
は、液体状の坐剤をコンテナ入口よりコンテナ内に注入
して固化させる工程と、前記坐剤と前記コンテナとの間
の空間に前記コンテナ入口を介して充填材を充填する工
程と、前記コンテナ入口をシールする工程とを含むこと
を特徴とする。なお、前記コンテナ入口は前記充填材と
共にシールされることが好ましい。The method for producing a suppository package of the present invention comprises the steps of: injecting a liquid suppository into a container from a container entrance to solidify; and filling the space between the suppository and the container with the suppository. The method includes the steps of: filling a filler through a container entrance; and sealing the container entrance. Preferably, the container inlet is sealed together with the filler.
【0009】[0009]
【発明の実施の形態】本発明者は、坐剤が保存又は流通
過程において体温以上の高温にさらされたときに変形す
るメカニズムについて詳細に研究したところ、坐剤の変
形は、坐剤と、該坐剤を包含する坐剤用コンテナとの間
の空隙の存在に起因することを突き止めた。すなわち、
内部に空隙が存在するコンテナ内で坐剤が溶融した場合
に該コンテナが横転又は天地逆転すると、該空隙部に坐
剤が移動して元の坐剤の形状が変形してしまい、この状
態で温度が降下すると、変形したままの状態で坐剤が硬
化するのである。DETAILED DESCRIPTION OF THE INVENTION The present inventors have studied in detail the mechanism by which a suppository deforms when exposed to a high temperature above body temperature during the storage or distribution process. It was ascertained that this was due to the presence of a gap between the suppository container and the suppository container. That is,
When the suppository is melted in a container having a void therein and the container is turned over or turned upside down, the suppository moves into the void and the shape of the original suppository is deformed. When the temperature drops, the suppository hardens while still deformed.
【0010】ここで、図面を参照して坐剤用コンテナ内
の空隙の発生について説明する。図1は従来のタイプの
坐剤梱包体及びその製造過程を示す縦断面図であり、図
1(a)は坐剤1が所定量だけ充填された、シール前の坐
剤用コンテナ2を示す。一方、図1(b)は図1(a)におけ
るX−X線に沿って坐剤用コンテナ2の入口2aをシー
ルした状態を示す。Here, generation of voids in the suppository container will be described with reference to the drawings. FIG. 1 is a longitudinal sectional view showing a conventional type suppository package and a manufacturing process thereof. FIG. 1 (a) shows a suppository container 2 before sealing, in which a suppository 1 is filled by a predetermined amount. . On the other hand, FIG. 1B shows a state where the entrance 2a of the suppository container 2 is sealed along the line XX in FIG. 1A.
【0011】従来のタイプの坐剤梱包体は、図1に示す
ように、坐剤用コンテナ2内に高温の溶融した坐剤1を
導入し、次いで室温で冷却して坐剤1を固化させ、その
後、坐剤用コンテナ2の入口2aをシールすることによ
って製造されている。したがって、図1から明らかなよ
うに、坐剤用コンテナ2内の空間を坐剤1が完全に満た
さない状態でその入口2aをシールすると、必然的に坐
剤用コンテナ2内に空隙3が形成される。そこで、空隙
3の発生を回避するためには、坐剤梱包体の製造にあた
って坐剤用コンテナ2内に坐剤1を密に充填することが
考えられる。In a conventional type of suppository package, as shown in FIG. 1, a high-temperature molten suppository 1 is introduced into a suppository container 2, and then cooled at room temperature to solidify the suppository 1. Then, it is manufactured by sealing the entrance 2a of the suppository container 2. Therefore, as is apparent from FIG. 1, when the entrance 2a is sealed in a state where the suppository 1 is not completely filled in the space in the suppository container 2, the space 3 is necessarily formed in the suppository container 2. Is done. Therefore, in order to avoid the generation of the voids 3, it is conceivable that the suppository 1 is densely filled in the suppository container 2 in manufacturing the suppository package.
【0012】しかしながら、図1において、坐剤用コン
テナ2内に坐剤1を密に充填すると、入口2aをシール
して製品とする際に坐剤1を挟み込んだ状態で入口2a
がシールされてしまい、坐剤用コンテナ2のシールが不
完全となる問題が発生する。一方、図1(a)においてY
−Y線に沿って坐剤用コンテナ2の入口2aをシールし
た場合は、たしかに空隙3の容積は減少するが、やはり
入口2aが坐剤1の一部を挟み込んで坐剤用コンテナ2
のシールが不完全となる。仮に、坐剤1の挟み込みが無
い状態でY−Y線に沿って坐剤用コンテナ2をシールで
きたとしても、溶融状態にある坐剤1が固化する際にそ
の端部表面が凹状に陥没することは避けられないので、
坐剤用コンテナ2内の一部には空隙が残存してしまう。However, in FIG. 1, when the suppository 1 is densely filled in the suppository container 2, the suppository 1 is sandwiched between the suppository 1 and the entrance 2a when the entrance 2a is sealed to obtain a product.
Is sealed, and the problem of incomplete sealing of the suppository container 2 occurs. On the other hand, in FIG.
-When the entrance 2a of the suppository container 2 is sealed along the line Y, the volume of the space 3 is certainly reduced, but the entrance 2a also sandwiches a part of the suppository 1
Seal is incomplete. Even if the suppository container 2 can be sealed along the line Y-Y without the suppository 1 being pinched, the end surface of the suppository 1 in a molten state is depressed into a concave shape when the suppository 1 in the molten state is solidified. It is inevitable that
A void remains in a part of the suppository container 2.
【0013】すなわち、従来タイプの坐剤梱包体を製造
する場合は、坐剤1の挟み込みを防いで坐剤用コンテナ
2の入口2aのシールを完全とする点に限ってみれば、
坐剤用コンテナ2内の空隙3はできるだけ大きい方が好
ましいのである。したがって、従来タイプの坐剤梱包体
を製造するにあたって、坐剤1を坐剤用コンテナ2に密
に充填することは坐剤用コンテナ2のシール性の点から
みて実施できない。That is, in the case of manufacturing a conventional type suppository package, if the suppository 1 is prevented from being pinched and the seal at the entrance 2a of the suppository container 2 is completely sealed,
The space 3 in the suppository container 2 is preferably as large as possible. Therefore, in manufacturing a conventional type suppository package, it is not possible to densely fill the suppository container 2 with the suppository 1 in view of the sealing property of the suppository container 2.
【0014】そこで、本発明者は次に、坐剤用コンテナ
内に空隙が発生することなく、かつ、該コンテナのシー
ルを完全に実施できる新規な坐剤梱包体及びその製造方
法について鋭意検討した結果、坐剤と坐剤用コンテナ内
面との間の空間に充填材を封入させた状態で該コンテナ
入口をシールする方法が有用であることを見出した。[0014] The inventor of the present invention has intensively studied a new suppository package and a method for producing the same, which can completely seal the suppository container without generating a void in the suppository container. As a result, it has been found that a method of sealing the entrance of the suppository with the filler filled in the space between the suppository and the inner surface of the suppository container is useful.
【0015】図2は本発明に係る坐剤梱包体5及びその
製造方法の一実施の形態を示す縦断面図であり、図2
(a)は坐剤用コンテナ2の入口2aがシールされる前の
状態を示す。一方、図2(b)は図2(a)におけるX−X線
に沿って坐剤用コンテナ2の入口2aが後述するように
充填材4と共にシールされシール部2a’とされた坐剤
梱包体5を示す。FIG. 2 is a longitudinal sectional view showing one embodiment of the suppository package 5 and the method for producing the same according to the present invention.
(a) shows a state before the entrance 2a of the suppository container 2 is sealed. On the other hand, FIG. 2 (b) shows a suppository package in which the entrance 2a of the suppository container 2 is sealed together with the filler 4 along the line XX in FIG. Figure 5 shows the body 5.
【0016】図2に示す実施の形態では、坐剤用コンテ
ナ2は同一形状の凹部を有する2枚のシートが該凹部を
向かい合わせた状態で貼り合わされて構成されており、
該凹部によって形成される空間内に坐剤1が保持され
る。ただし、前記シートの一部は相互に貼り合わされ
ず、前記空間への入口2aを構成する。なお、前記空間
の形状は特に限定されるものではないが、坐剤1の使用
を容易とするためには、略紡錘形であることが好まし
い。In the embodiment shown in FIG. 2, the suppository container 2 is composed of two sheets having a concave portion having the same shape and bonded together with the concave portions facing each other.
The suppository 1 is held in the space formed by the recess. However, a part of the sheets is not bonded to each other and forms an entrance 2a to the space. The shape of the space is not particularly limited, but is preferably substantially spindle-shaped to facilitate use of the suppository 1.
【0017】坐剤用コンテナ2の材質は特に限定される
ものではなく、例えばポリエチレン、ポリプロピレン、
ポリ塩化ビニル、ポリスチレン、ポリエステル等の汎用
の合成樹脂材料等を使用することが可能であるが、ヒー
トシール可能な点では、ポリエチレン、ポリプロピレン
等のポリオレフィン系の合成樹脂材料が好ましい。ま
た、坐剤用コンテナ2を構成するシートは複数の異なる
材質からなるシートの積層体であってもよい。The material of the suppository container 2 is not particularly limited. For example, polyethylene, polypropylene,
Although general-purpose synthetic resin materials such as polyvinyl chloride, polystyrene, and polyester can be used, polyolefin-based synthetic resin materials such as polyethylene and polypropylene are preferable from the viewpoint of heat sealing. Further, the sheets constituting the suppository container 2 may be a laminate of sheets made of a plurality of different materials.
【0018】本発明においては、坐剤用コンテナ2に保
持される坐剤1の基剤及びそこに配合される薬剤の種類
は特に限定されない。前記基剤としては、例えばカプリ
ル酸、カプリン酸、ペラゴン酸、ウンデシル酸、トリデ
シル酸、ラウリン酸、ミリスチン酸、パルミチン酸、ペ
ンタデシル酸、ヘプタデシル酸、ステアリン酸、オレイ
ン酸、エライジン酸、リノール酸、リノレイン酸等の不
飽和脂肪酸又は不飽和脂肪酸グリセリンエステルを挙げ
ることができる。これらは必要に応じて1種又は2種以
上を適宜混合して使用することができ、また、通常は不
飽和又は飽和脂肪酸とグリセリンとのモノ、ジ及びトリ
エステルの混合物が好ましい。In the present invention, the base of the suppository 1 held in the suppository container 2 and the kind of the drug mixed therein are not particularly limited. Examples of the base include caprylic acid, capric acid, pelagonic acid, undecylic acid, tridecylic acid, lauric acid, myristic acid, palmitic acid, pentadecylic acid, heptadecylic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, and linoleic acid. Examples include unsaturated fatty acids such as acids and unsaturated fatty acid glycerin esters. These can be used alone or in admixture of two or more, if necessary. Usually, a mixture of mono-, di- and triesters of unsaturated or saturated fatty acid and glycerin is preferable.
【0019】前記基剤には、非イオン性界面活性剤、カ
チオン性界面活性剤又はアニオン性界面活性剤の1種又
は2種以上を添加することが可能であるが、坐剤1の溶
融液の分散安定性等の点では、グリセリン脂肪酸エステ
ル、プロピレングリコール脂肪酸エステル、ソルビタン
脂肪酸エステル、ポリオキシエチレンソルビタン脂肪酸
エステル、ポリオキシエチレン脂肪酸エステル、ポリオ
キシエチレン脂肪酸アルコールエーテル、ポリオキシエ
チレンアルキルフェニルエーテル、ポリオキシエチレン
ヒマシ油等の非イオン性界面活性剤を使用することが好
ましい。The base may contain one or more of a nonionic surfactant, a cationic surfactant and an anionic surfactant. Glycerin fatty acid ester, propylene glycol fatty acid ester, sorbitan fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene fatty acid ester, polyoxyethylene fatty acid alcohol ether, polyoxyethylene alkyl phenyl ether, polyoxyethylene alkyl phenyl ether, It is preferred to use a non-ionic surfactant such as oxyethylene castor oil.
【0020】坐剤1の硬度又は使用感、並びに、坐剤1
からの薬物の放出性及び安定性を改善するために、前記
基剤には油性成分を添加することが好ましい。前記油性
成分としては、ゴマ油、オリーブ油、ツバキ油、ダイズ
油、ナタネ油、綿実油、アマニ油、ヒマシ油、ヌカ油、
トウモロコシ油、落花生油、ヤシ油、アーモンド油、ア
ボガード油、パーム油、パーム核油、カヤ油、カホツク
油、クロモジ油、サザンカ油、チヤ油、エノ油、カカオ
脂、ニツケイ脂、ラウリン脂、牛脂、豚脂、羊毛脂、タ
ートル油、スクワレン等の動植物油脂や、これらの動植
物油脂を水素添加、脂肪酸変換、アセチル化、分割抽出
等により化学的に変化させて得られる改質油脂、ワセリ
ン、白色ワセリン、流動パラフィン、パラフィン、脱水
ラノリン、アイソバー、シリコン脂等の鉱物油、イソプ
ロピルミリステート、ノルマルブチルミリステート、イ
ソプロピルリノレート、ステアリルリノレート、ジエチ
ルセバケート、ジイソプロピルアジベート、セチルアル
コール、ステアリルアルコール、サラシミツロウ、ゲイ
ロウ、モクロウ等の高級脂肪族アルコール、高級脂肪酸
エステル、ワックス類、ステアリン酸、オレイン酸、パ
ルミチン酸等の高級脂肪酸等が挙げられる。これらは必
要に応じて1種又は2種以上を混合して使用してもよ
い。Hardness or feeling of use of suppository 1 and suppository 1
It is preferable to add an oil component to the base in order to improve the release property and stability of the drug from the base. As the oily component, sesame oil, olive oil, camellia oil, soybean oil, rapeseed oil, cottonseed oil, linseed oil, castor oil, bran oil,
Corn oil, peanut oil, coconut oil, almond oil, avoguard oil, palm oil, palm kernel oil, kaya oil, kahotsuku oil, kuromoji oil, sasanqua oil, cinnamon oil, eno oil, cocoa oil, nitsukei oil, laurin oil, tallow oil Animal and vegetable fats such as lard, wool fat, turtle oil and squalene, and modified fats and oils, vaseline, white obtained by chemically changing these animal and vegetable fats by hydrogenation, fatty acid conversion, acetylation, split extraction, etc. Vaseline, liquid paraffin, paraffin, dehydrated lanolin, isobar, mineral oils such as silicone oil, isopropyl myristate, normal butyl myristate, isopropyl linoleate, stearyl linoleate, diethyl sebacate, diisopropyl adipate, cetyl alcohol, stearyl alcohol, Salami beeswax, gay wax, mokuro etc. Higher aliphatic alcohols, higher fatty acid esters, waxes, stearic acid, oleic acid, higher fatty acids such as palmitic acid. These may be used alone or in combination of two or more as necessary.
【0021】坐剤1に配合される薬物は治療等の対象に
応じて適宜選択されるが、例えば、ジクロフェナックナ
トリウム、ピロキシカム、アセトアミノフェン、インド
メタシン、ケトプロフェン、塩酸ブプレノルフィン、イ
ブプロフェン、アスピリン等の解熱鎮痛消炎剤、吉草酸
ジフルコルトロン、酢酸ヒドロコルチドン、ベタメタゾ
ン等の副腎皮質ホルモン剤、塩酸モルヒネ等のあへんア
ルカロイド系麻薬、ドンペリゾン等の消化器官用剤、テ
ガフール、フルオロウラシル等の代謝拮抗剤、ゲメプロ
スト等のホルモン剤、ジアゼパム、フェノバルビタール
等の催眠鎮静剤・抗不安剤、ビサコジル等の下剤・浣腸
剤、サラゾスルファピリジン等のサルファ剤、セフチゾ
キシムナトリウム等の抗生物質、アミノフィリン等の気
管支拡張剤、トリベノシド、プロクトセディル、大腸菌
死菌、シコンエキス、ロートエキス等の痔疾用剤が挙げ
られる。坐剤1には必要に応じて、局所麻酔薬、抗ヒス
タミン剤、殺菌剤、ビタミン剤、アミノ酸類、胆汁酸類
等の薬物を更に添加してもよい。さらに、坐剤1には必
要に応じて他の補助成分を添加することもできる。前記
補助成分としては水、安定化剤、保存剤、着色剤、芳香
剤、分散剤、増粘剤、pH調節剤、湿潤剤、抗酸化剤、
防腐剤、賦形剤等が挙げられる。The drug to be incorporated in the suppository 1 is appropriately selected according to the target of treatment or the like. For example, antipyretic analgesia such as diclofenac sodium, piroxicam, acetaminophen, indomethacin, ketoprofen, buprenorphine hydrochloride, ibuprofen, aspirin and the like Anti-inflammatory agents, diflucortron valerate, hydrocortidone acetate, betamethasone, etc., corticosteroids such as morphine hydrochloride, alkaloid narcotics such as morphine, drugs for digestive organs such as domperisone, antimetabolites such as tegafur, fluorouracil, gemeprost Hormones such as diazepam, phenobarbital, etc., hypnotics and anxiolytics such as diazepam, physicians and enemas such as bisacodyl, sulfa drugs such as salazosulfapyridine, antibiotics such as ceftizoxime sodium, and bronchodilation such as aminophylline Agent, bird Noshido, Purokutosediru, E. coli killed, Shikonekisu, hemorrhoid agents such as scopolia extract and the like. If necessary, the suppository 1 may further contain a drug such as a local anesthetic, an antihistamine, a bactericide, a vitamin, amino acids, and bile acids. Further, other auxiliary ingredients can be added to the suppository 1 as needed. Water, stabilizers, preservatives, coloring agents, fragrances, dispersants, thickeners, pH regulators, wetting agents, antioxidants,
Preservatives, excipients and the like can be mentioned.
【0022】本実施の形態における坐剤梱包体5は以下
のようにして製造される。まず、坐剤用コンテナ2の入
口2aを鉛直上方に開口させた状態で、図示しないノズ
ルを介して溶融状態の坐剤1が坐剤用コンテナ2内の空
間に導入される。坐剤1は坐剤用コンテナ2内の空間に
完全には充填されず、その底部からある程度の高さまで
充填される。その後、坐剤1は室温で冷却されて固化さ
れる。次に、図示しない供給手段を介して充填材4が坐
剤用コンテナ2に残存する空間に密に充填される。この
ように、本実施の形態においては、坐剤1が固化する際
に生じる端部表面の凹状陥没部分についても完全に充填
材4によって満たされるので、坐剤用コンテナ2内に空
隙が残存することがない。The suppository package 5 in the present embodiment is manufactured as follows. First, with the inlet 2a of the suppository container 2 opened vertically upward, the suppository 1 in a molten state is introduced into the space in the suppository container 2 via a nozzle (not shown). The suppository 1 is not completely filled in the space inside the suppository container 2, but is filled to a certain height from the bottom. Thereafter, the suppository 1 is cooled at room temperature and solidified. Next, the filler 4 is densely filled in the space remaining in the suppository container 2 via a supply means (not shown). As described above, in the present embodiment, since the concave portion of the end surface generated when the suppository 1 is solidified is completely filled with the filler 4, a void remains in the suppository container 2. Nothing.
【0023】充填材4の物理的性状は、坐剤用コンテナ
2内での坐剤1の移動を阻止するものであれば特に限定
されるものではなく、液状、ペースト状、又は、固形状
であってもよい。ただし、坐剤用コンテナ2内への導入
の容易性及び坐剤用コンテナ2のシールの容易性の点で
は液状又はペースト状のものが好ましい。一方、充填材
4は坐剤1と接触するので、人体に好ましくない成分が
坐剤1へ移行することを防止するために、充填材4の材
質は、水、有機溶媒、重合開始剤、架橋剤、未重合のモ
ノマー等の各種の成分の溶出が無いか、又は、あっても
きわめて少ないものとすることが好ましい。The physical properties of the filler 4 are not particularly limited as long as they prevent the movement of the suppository 1 in the suppository container 2, and may be in the form of a liquid, a paste, or a solid. There may be. However, from the viewpoint of easy introduction into the suppository container 2 and easy sealing of the suppository container 2, a liquid or paste-like one is preferable. On the other hand, since the filler 4 comes into contact with the suppository 1, the material of the filler 4 is water, an organic solvent, a polymerization initiator, It is preferable that various components such as an agent and an unpolymerized monomer are not eluted, or at all very little.
【0024】坐剤1の形状保持性及び開封時の取り扱い
の簡易性等の観点からは、充填材4は坐剤用コンテナ2
に対して接合されていることが好ましい。充填材4と坐
剤用コンテナ2との接合方法としては、充填材4の少な
くとも一部を接着剤を用いて坐剤用コンテナ2に接着す
る態様等を挙げることができるが、製造工程の簡略化の
点で、充填材4自体を坐剤用コンテナ2に対して付着性
乃至接着性を有する合成又は天然の高分子材料によって
構成することが好ましい。ただし、その場合には、充填
材4を構成する高分子材料は坐剤1に対しては付着乃至
接着しないことが好適である。From the viewpoint of the shape retention of the suppository 1 and the simplicity of handling at the time of opening, the filler 4 is used as the suppository container 2.
It is preferred to be joined to. Examples of a method of joining the filler 4 and the suppository container 2 include an embodiment in which at least a part of the filler 4 is adhered to the suppository container 2 using an adhesive, but the manufacturing process is simplified. From the viewpoint of conversion, the filler 4 itself is preferably made of a synthetic or natural polymer material having an adhesive property or an adhesive property to the suppository container 2. However, in this case, it is preferable that the polymer material constituting the filler 4 does not adhere to or adhere to the suppository 1.
【0025】充填材4を合成又は天然高分子材料によっ
て構成する場合には、該高分子材料の融点は50℃〜1
50℃の範囲にあることが好ましい。融点が50℃未満
では坐剤梱包体の保存乃至流通過程において充填材4が
溶融して坐剤1と一体化するおそれがある。また、融点
が150℃を越えると坐剤用コンテナ2内への導入時
に、坐剤1を熱変質等させるおそれがある。なお、前記
合成又は天然高分子材料としては、坐剤用コンテナ2へ
の接着性、入口2aのシール性等の点でホットメルト型
接着剤が特に好ましい。本発明におけるホットメルト型
接着剤としては、加熱により溶融して接着性を発揮し冷
却により固化して接着状態を維持するものの他にいわゆ
る反応性ホットメルト型接着剤を使用することができ
る。そのようなホットメルト型接着剤としては、例え
ば、ポリエチレン、ポリプロピレン、ポリイソブチレン
等のオレフィン樹脂系接着剤、ポリイソブチレンポリア
ミド、ナイロン−11、ナイロン−12等のポリアミド
系接着剤、アクリル樹脂系接着剤、ポリ酢酸ビニル系接
着剤、ポリエステル系接着剤、ポリビニルブチラール等
のポリビニルアセタール系接着剤、エチレン−酢酸ビニ
ル共重合体系接着剤、熱可塑性エラストマー系接着剤、
ウレタン系反応性ホットメルト接着剤等が挙げられる
が、人体に有害な溶出成分を含まないものであることが
好ましい。When the filler 4 is made of a synthetic or natural polymer material, the melting point of the polymer material is 50 ° C. to 1 ° C.
Preferably it is in the range of 50 ° C. If the melting point is less than 50 ° C., the filler 4 may be melted and integrated with the suppository 1 during the storage or distribution of the suppository package. On the other hand, if the melting point exceeds 150 ° C., the suppository 1 may be thermally deteriorated when introduced into the suppository container 2. As the synthetic or natural polymer material, a hot-melt adhesive is particularly preferable in terms of adhesiveness to the suppository container 2, sealing property of the entrance 2a, and the like. As the hot-melt adhesive in the present invention, a so-called reactive hot-melt adhesive can be used, in addition to one that melts by heating to exhibit adhesiveness and solidifies by cooling to maintain an adhesive state. Examples of such hot melt adhesives include olefin resin adhesives such as polyethylene, polypropylene and polyisobutylene, polyamide adhesives such as polyisobutylene polyamide, nylon-11 and nylon-12, and acrylic resin adhesives. , Polyvinyl acetate adhesive, polyester adhesive, polyvinyl acetal adhesive such as polyvinyl butyral, ethylene-vinyl acetate copolymer adhesive, thermoplastic elastomer adhesive,
Examples thereof include urethane-based reactive hot melt adhesives and the like, and preferably do not contain elution components harmful to the human body.
【0026】本実施の形態においては、図2(a)に示さ
れるように、充填材4が坐剤1と坐剤用コンテナ2との
間の空間に完全に充填されると、同図のX−X線に沿っ
て坐剤用コンテナ2の入口2aがシールされる。入口2
aのシール方法としては、接着剤による封止、加熱手段
との接触乃至押圧によるヒートシール、締結部材による
閉止等の様々な方法が採用可能であるが、シール操作の
容易性及び確実性等の点でヒートシールとすることが好
ましい。なお、坐剤用コンテナ2の入口2aをヒートシ
ールによって封止する場合には、坐剤用コンテナ2の少
なくとも入口2aの部分は、加熱により溶融して接着性
を発揮する材質とされている必要がある。In the present embodiment, as shown in FIG. 2 (a), when the filler 4 is completely filled in the space between the suppository 1 and the suppository container 2, The entrance 2a of the suppository container 2 is sealed along the line XX. Entrance 2
As the sealing method a, various methods such as sealing with an adhesive, heat sealing by contact or pressing with a heating means, closing with a fastening member, etc. can be adopted. In this respect, heat sealing is preferable. When the entrance 2a of the suppository container 2 is sealed by heat sealing, at least a portion of the entrance 2a of the suppository container 2 needs to be made of a material which is melted by heating to exhibit adhesiveness. There is.
【0027】そして最後に、坐剤用コンテナ2の入口2
aがシールされてシール部2a’となることにより、図
2(b)に示すように、本発明に係る坐剤梱包体5が製造
される。坐剤用コンテナ2内の空間には充填材4が密に
充填されているので、入口2aのシール時には、充填材
4の一部がシール部分に挟み込まれ、共にシールされる
が、充填材4自体がシール材としての機能を有している
ために、坐剤梱包体5の密封性は保存又は流通過程にお
いて完全に維持される。Finally, the entrance 2 of the suppository container 2
As a is sealed to form the seal portion 2a ', the suppository package 5 according to the present invention is manufactured as shown in FIG. 2 (b). Since the space inside the suppository container 2 is densely filled with the filler 4, when the inlet 2a is sealed, a part of the filler 4 is sandwiched between the sealing portions and sealed together. Since the suppository package 5 itself has a function as a sealing material, the hermeticity of the suppository package 5 is completely maintained during the storage or distribution process.
【0028】このようにして製造された坐剤梱包体5に
おいては、充填材4がシール部2a’を介して坐剤用コ
ンテナ2内に封入されているので、充填材4は坐剤用コ
ンテナ2のシール部2a’と一体化して、坐剤用コンテ
ナ2のシールをより確実なものとする。したがって、坐
剤と外界との接触を完全に断つことが可能となるので、
坐剤用コンテナ2の内部に収容された坐剤1を使用時ま
で安全かつ良好な状態で保持することができる。In the suppository package 5 manufactured as described above, the filler 4 is sealed in the suppository container 2 via the seal portion 2a '. 2 and a seal part 2a 'of the suppository container 2 to make the seal more secure. Therefore, it is possible to completely cut off the contact between the suppository and the outside world,
The suppository 1 contained in the suppository container 2 can be held in a safe and good state until use.
【0029】また、図2(b)から明らかなように、本実
施の形態の坐剤梱包体5ではその内部に坐剤1が移動可
能な空間が存在しないので、保存乃至流通過程において
坐剤梱包体5が体温以上の温度条件下におかれて、坐剤
1が溶融した場合であっても、坐剤用コンテナ2内で坐
剤1が移動することがない。したがって、高温下で坐剤
梱包体5が横転又は天地逆転しても坐剤1の元の形状を
維持することができる。Further, as is clear from FIG. 2 (b), in the suppository package 5 of the present embodiment, there is no space in which the suppository 1 can move, so that the suppository can be stored or distributed in the course of storage or distribution. Even when the suppository 1 is melted when the package 5 is placed at a temperature equal to or higher than the body temperature, the suppository 1 does not move in the suppository container 2. Therefore, the original shape of the suppository 1 can be maintained even when the suppository package 5 is turned over or turned upside down at a high temperature.
【0030】さらに、本実施の形態の坐剤梱包体5にお
いては、充填材4が坐剤用コンテナ2と一体化している
ので、図3に示すように、使用時に坐剤用コンテナ2を
開封しても充填材4が坐剤用コンテナ2から外れること
がない。したがって、使用者が坐剤用コンテナ2から坐
剤1を取り出す際に、充填材4を誤って取り出すおそれ
がない。また、坐剤1を取り出した後の坐剤梱包体の廃
棄処理等も容易である。しかも、充填材4が坐剤用コン
テナ2に固定されているので、保存又は流通段階におい
て充填材4が移動して坐剤1の形状に影響を与えること
がない。Further, in the suppository package 5 of the present embodiment, since the filler 4 is integrated with the suppository container 2, the suppository container 2 is opened when used as shown in FIG. Even if it does, the filler 4 does not come off from the suppository container 2. Therefore, when the user takes out the suppository 1 from the suppository container 2, there is no possibility that the filler 4 will be taken out by mistake. Further, disposal of the suppository package after taking out the suppository 1 is also easy. In addition, since the filler 4 is fixed to the suppository container 2, the filler 4 does not move during the storage or distribution stage and does not affect the shape of the suppository 1.
【0031】[0031]
【実施例】実施例に用いた坐剤は常法により調製した。
その組成と性状を表1に示す。次に、ポリエチレンを内
側にラミネートしたポリプロピレン製の坐剤用コンテナ
に1.5gの溶融した坐剤を充填した。前記坐剤の固化
後、この上に溶融したポリ酢酸ビニル系のホットメルト
型接着剤0.5gを素速く充填し、直ちにヒートシーラ
ーで坐剤用コンテナ入口を密封して坐剤梱包体を得た。EXAMPLES The suppositories used in the examples were prepared by a conventional method.
The composition and properties are shown in Table 1. Next, a polypropylene suppository container having polyethylene laminated inside was filled with 1.5 g of molten suppository. After the suppository was solidified, 0.5 g of the molten polyvinyl acetate hot melt adhesive was quickly filled thereon, and the suppository container inlet was immediately sealed with a heat sealer to obtain a suppository package. Was.
【表1】 [Table 1]
【0032】上記のようにして得られた坐剤梱包体20
個を、天地を逆転して45℃の恒温槽に1時間保存した
後に25℃の室内に1日間静置した。その結果、試験に
供した20個のサンプルのいずれについても、坐剤用コ
ンテナからの坐剤の漏洩はなかった。また、坐剤用コン
テナから坐剤を取り出したところ、坐剤には変形が認め
られなかった。The suppository package 20 obtained as described above
The pieces were stored upside down in a 45 ° C. constant temperature bath for 1 hour, and then left standing in a room at 25 ° C. for 1 day. As a result, there was no leakage of the suppository from the suppository container in any of the 20 samples subjected to the test. When the suppository was taken out of the suppository container, no deformation was observed in the suppository.
【0033】[0033]
【発明の効果】本発明の坐剤梱包体によれば、坐剤梱包
体が体温以上の温度条件下で保存乃至流通され、横転又
は天地逆転されたとしても、坐剤用コンテナ内に保持さ
れる坐剤の形状が変形することがない。According to the suppository package of the present invention, even if the suppository package is stored or distributed under a temperature condition equal to or higher than the body temperature, and is turned over or turned upside down, it is held in the suppository container. Suppository does not deform.
【0034】坐剤用コンテナ内の充填材が坐剤用コンテ
ナと接合されている場合は、使用者が坐剤用コンテナか
ら坐剤を取り出す際に、充填材を誤って取り出すおそれ
がなく、また、使用後の廃棄処理等を容易に行うことが
できる。さらに、充填材が坐剤用コンテナ内で移動する
ことがないので坐剤の形状に影響を与えることがない。
特に、前記充填材が坐剤用コンテナのシール部と一体化
している場合には、上記した効果の他に、該シール部の
封止がより確実となり、坐剤を外界から遮断してより安
全に保持することが可能となる。When the filler in the suppository container is joined to the suppository container, there is no danger that the filler may be removed by mistake when the user removes the suppository from the suppository container. In addition, disposal after use can be easily performed. Further, since the filler does not move in the suppository container, the shape of the suppository is not affected.
In particular, in the case where the filler is integrated with the seal portion of the suppository container, in addition to the effects described above, the sealing of the seal portion becomes more secure, and the suppository is shielded from the outside world, thereby providing a more secure Can be held.
【0035】前記充填材が溶出成分を含まない場合に
は、人体に好ましくない化学物質等が坐剤へ移行するこ
とを回避することができる。また、前記充填材がホット
メルト型接着剤である場合には、坐剤用コンテナとの一
体化及びシールを容易に行うことができる。When the filler does not contain an eluting component, it is possible to avoid the transfer of a chemical substance or the like which is undesirable for the human body to a suppository. In addition, when the filler is a hot-melt adhesive, integration with the suppository container and sealing can be easily performed.
【0036】本発明の坐剤梱包体の製造方法によれば、
体温以上の温度条件下で保存乃至流通され、横転又は天
地逆転されたとしても、坐剤の形状が崩れることがない
坐剤梱包体を得ることができる。特に、コンテナ入口を
充填材と共にシールする場合には、該シール部の封止を
より確実に行うことができる。According to the method for producing a suppository package of the present invention,
It is possible to obtain a suppository package in which the shape of the suppository is not lost even if the suppository is stored or distributed under a temperature condition equal to or higher than the body temperature and turned over or upside down. In particular, when the container entrance is sealed with the filler, the sealing portion can be more reliably sealed.
【図1】 従来タイプの坐剤梱包体及びその製造過程を
示す縦断面図。FIG. 1 is a longitudinal sectional view showing a conventional type suppository package and a manufacturing process thereof.
【図2】 本発明に係る坐剤梱包体及びその製造方法の
一実施の形態を示す縦断面図。FIG. 2 is a longitudinal sectional view showing one embodiment of a suppository package and a method for producing the same according to the present invention.
【図3】 本発明の坐剤梱包体の開封状態を示す縦断面
図。FIG. 3 is a longitudinal sectional view showing an opened state of the suppository package of the present invention.
1 坐剤 2 坐剤用コンテナ 3 空隙 4 充填材 5 坐剤梱包体 DESCRIPTION OF SYMBOLS 1 Suppository 2 Suppository container 3 Void 4 Filler 5 Suppository package
Claims (7)
って、 前記坐剤と前記コンテナとの間の空間に充填材が封入さ
れていることを特徴とする坐剤梱包体。1. A suppository package comprising a suppository and a container containing the suppository, wherein a filler is sealed in a space between the suppository and the container. Suppository packaging.
いることを特徴とする請求項1記載の坐剤梱包体。2. The suppository package according to claim 1, wherein the filler is bonded to the container.
前記充填材が該シール部と一体化されていることを特徴
とする請求項1又は2記載の坐剤梱包体。3. The container has a seal portion,
The suppository package according to claim 1 or 2, wherein the filler is integrated with the seal portion.
特徴とする請求項1乃至3のいずれかに記載の坐剤梱包
体。4. The suppository package according to claim 1, wherein the filler does not contain an eluted component.
ることを特徴とする請求項1乃至4のいずれかに記載の
坐剤梱包体。5. The suppository package according to claim 1, wherein the filler is a hot-melt adhesive.
ナ内に注入して固化させる工程と、 前記坐剤と前記コンテナとの間の空間に前記コンテナ入
口を介して充填材を充填する工程と、 前記コンテナ入口をシールする工程とを含む坐剤梱包体
の製造方法。6. A step of injecting a liquid suppository into the container from a container inlet to solidify, and a step of filling a space between the suppository and the container with a filler through the container inlet. And a step of sealing the container entrance.
いて、前記充填材と共に前記コンテナ入口をシールする
ことを特徴とする請求項6記載の坐剤梱包体の製造方
法。7. The method for producing a suppository package according to claim 6, wherein in the step of sealing the container entrance, the container entrance is sealed together with the filler.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11078691A JP2000271189A (en) | 1999-03-23 | 1999-03-23 | Suppository packing body and manufacture therefor |
AU33256/00A AU3325600A (en) | 1999-03-23 | 2000-03-23 | Suppository package and production method therefor |
PCT/JP2000/001761 WO2000056263A1 (en) | 1999-03-23 | 2000-03-23 | Suppository package and production method therefor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11078691A JP2000271189A (en) | 1999-03-23 | 1999-03-23 | Suppository packing body and manufacture therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2000271189A true JP2000271189A (en) | 2000-10-03 |
Family
ID=13668901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP11078691A Pending JP2000271189A (en) | 1999-03-23 | 1999-03-23 | Suppository packing body and manufacture therefor |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP2000271189A (en) |
AU (1) | AU3325600A (en) |
WO (1) | WO2000056263A1 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2142034A1 (en) * | 1971-08-21 | 1973-03-01 | Franco Pozzi | PROCESS FOR THE CONTINUOUS MANUFACTURING OF CONTAINERS FROM PLASTIC MATERIAL, IN PARTICULAR FOR SUPPOSITORIES AND THE LIKE. AND DEVICE FOR CARRYING OUT THE PROCEDURE |
JPS5882869A (en) * | 1981-11-06 | 1983-05-18 | 岡本 「あ」吉 | Suppository molding packing |
JPH078292B2 (en) * | 1987-04-16 | 1995-02-01 | 光雄 松本 | Hollow suppository container and manufacturing method thereof |
JPH0640892B2 (en) * | 1990-05-31 | 1994-06-01 | 大正製薬株式会社 | Suppository molded package and suppository container |
-
1999
- 1999-03-23 JP JP11078691A patent/JP2000271189A/en active Pending
-
2000
- 2000-03-23 AU AU33256/00A patent/AU3325600A/en not_active Abandoned
- 2000-03-23 WO PCT/JP2000/001761 patent/WO2000056263A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
AU3325600A (en) | 2000-10-09 |
WO2000056263A1 (en) | 2000-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4439194A (en) | Water and drug delivery system for suppository use | |
US20100044924A1 (en) | Candle refill kit and method of use | |
US4695450A (en) | Anhydrous emulsions and the use thereof | |
US4663148A (en) | Dispenser comprising telescopically engaging members | |
KR100379777B1 (en) | Lubrication Aid | |
US5254346A (en) | Occlusive body for administering a physiologically active substance | |
EP0153200A2 (en) | Medicinal patch | |
US4663149A (en) | Dispenser comprising inner and outer walls functioning as cooperative unit | |
US4814180A (en) | Agent dispenser comprising a semipermeable wall surrounding single-piece or two-piece container | |
US5827535A (en) | Graphically impressed softgel and method for making same | |
JPH0825868B2 (en) | Device for administration of heat-reactive composition | |
ZA200204662B (en) | Injection-moulded water-soluble container. | |
EP0103995B1 (en) | Medicated suppository | |
PL163710B1 (en) | Specific for liberation and/or introducing of substancesof contact hot-melt adhesives and method of that specific manufacture | |
SK286071B6 (en) | Pharmaceutical composition comprising testosterone undecanoate | |
CA1252359A (en) | Agent dispenser comprising a multiplicity of members performing as an integrated unitary system | |
US20050271594A1 (en) | Abuse resistent pharmaceutical composition | |
KR920007832B1 (en) | Process for preparing hot melt compositions of terfenadine | |
US3061510A (en) | Radioactive iodinated (i131) fatty material admixed with wax-like material in capsule | |
US4800056A (en) | Process for making dispenser with cooperating elements | |
US4678467A (en) | Dispenser comprising capsule with volume displacing member | |
JP2000271189A (en) | Suppository packing body and manufacture therefor | |
JPS5883634A (en) | Novel solid pharmacognosical shape for oral administration and manufacture | |
US4692326A (en) | Dispenser comprising inner positioned soft or hard capsule | |
GB1590864A (en) | Thixotropic filling medium for hard gelatin capsules |